



ASX ANNOUNCEMENT

Lumos signs three new agreements with Hologic

MELBOURNE, Australia (16 March 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) is pleased to announce it has entered into three new agreements with US-based women’s healthcare company Hologic that will provide Lumos with up to US\$5.9 million in total in non-dilutive funding.

Lumos and Hologic have signed a sale and leaseback agreement for some of Lumos’ capital equipment that will provide Lumos with US\$4.2 million from the proceeds of the sale. The equipment, which is primarily for the development and manufacture of point-of-care diagnostic tests, will continue to be available and used by Lumos at its site in Carlsbad CA through a long-term lease arrangement with Hologic.

In addition to the sale and leaseback agreement, Hologic has signed two agreements worth up to \$1.7 million to undertake additional work on existing projects. These agreements follow the three service agreements between Hologic and Lumos that were signed during H1 FY2023.

“We are extremely grateful and appreciative of the ongoing support that Hologic has provided for Lumos through these agreements,” said Doug Ward, CEO of Lumos Diagnostics. “In addition to providing the Company with additional, non-dilutive funding that does not impact on our operational capacity, they further strengthen our strategic relationship with Hologic.”

This announcement has been approved by the Lumos Disclosure Committee.

-Ends-

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions.

Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598